Guardant Health Unveils Precision Oncology Advances at SABCS 2024 for Breast Cancer Treatment

Guardant Health Showcases Precision Oncology Innovations at SABCS 2024

Guardant Health, a leader in precision oncology based in Palo Alto, California, is set to present a range of significant advancements at the upcoming San Antonio Breast Cancer Symposium (SABCS) 2024, scheduled for December 10-13, 2024. The company will unveil eight research posters in collaboration with its research partners, with a particular emphasis on the Guardant Reveal test. This innovative tissue-free epigenomic assay focuses on circulating tumor DNA (ctDNA) dynamics during neoadjuvant endocrine therapy for hormone receptor-positive (HR+) early breast cancer. The findings from this research indicate that ctDNA analysis can provide essential insights into tumor burden, therapy sensitivity, and the presence of resistance mutations, positioning it as a crucial tool for predicting long-term patient outcomes and tailoring personalized treatment strategies.

Dr. Craig Eagle, Chief Medical Officer at Guardant Health, highlights the company's commitment to enhancing treatment selection and monitoring for cancer recurrence and therapeutic responses through its precision oncology portfolio. The array of presentations at SABCS will address various critical topics, including the real-world outcomes of elacestrant treatment for advanced HR+ breast cancer, as well as genomic comparisons of patient responses to CDK4/6 inhibitors. A notable aspect of the presentations will be a comprehensive analysis of minimal residual disease testing involving 2,000 breast cancer patients, which aims to present valuable data on the real-world implications of ctDNA monitoring in clinical settings.

Guardant Health's commitment to advancing precision medicine in oncology is further illustrated by the diverse range of studies being presented. The company emphasizes collaboration with researchers and healthcare teams to improve outcomes for breast cancer patients. Featured products like GuardantINFORM™, Guardant Infinity™, and Guardant360® CDx will also be highlighted, reinforcing the company's role in optimizing therapy selection and enhancing patient management strategies within the landscape of breast cancer treatment.

In addition to the focus on ctDNA and its applications, Guardant Health aims to underline the importance of real-world data in understanding treatment efficacy. The company's innovative approaches not only seek to improve patient outcomes but also serve to bridge the gap between clinical research and everyday cancer care. As Guardant Health prepares for SABCS 2024, it continues to position itself at the forefront of precision oncology, dedicated to transforming how breast cancer is diagnosed and treated.